See more : Genex Power Limited (GNX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Silo Pharma, Inc. (SILO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silo Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aviva plc (AVVIY) Income Statement Analysis – Financial Results
- Mitsubishi Heavy Industries, Ltd. (7011.T) Income Statement Analysis – Financial Results
- Energiedienst Holding AG (0QOH.L) Income Statement Analysis – Financial Results
- TROOPS, Inc. (TROO) Income Statement Analysis – Financial Results
- Yellowstone Acquisition Company (YSAC) Income Statement Analysis – Financial Results
Silo Pharma, Inc. (SILO)
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.10K | 72.10K | 71.26K | 40.92K | 40.57K | 0.00 | 847.41K | -669.48K | -145.19K | -107.11K | 105.52K | 0.00 | 0.00 |
| Cost of Revenue | 5.84K | 5.84K | 5.00K | 176.13K | 27.39K | 17.55K | 0.00 | 0.00 | 0.00 | -127.68K | 104.90K | 0.00 | 0.00 |
| Gross Profit | 66.26K | 66.26K | 66.26K | -135.20K | 13.18K | -17.55K | 847.41K | -669.48K | -145.19K | 20.57K | 625.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 91.90% | 91.90% | 92.98% | -330.38% | 32.49% | 0.00% | 100.00% | 100.00% | 100.00% | -19.20% | 0.59% | 0.00% | 0.00% |
| Research & Development | 845.09K | 1.29M | 693.91K | 88.80K | 63.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Selling & Marketing | 0.00 | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Other Expenses | 0.00 | 2.17M | 1.95M | 3.00K | 765.72K | 314.61K | 177.50K | 142.50K | 96.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.92M | 3.71M | 2.96M | 2.27M | 927.65K | 459.83K | 490.87K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Cost & Expenses | 3.93M | 3.72M | 2.96M | 2.45M | 955.03K | 459.83K | 427.96K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Interest Income | 398.53K | 72.64K | 1.21K | 11.54K | 12.20K | 4.22K | 20.48K | 49.84K | 40.34K | 20.57K | 625.00 | 0.00 | 0.00 |
| Interest Expense | 4.87K | 2.20K | 3.04K | 269.27K | 62.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 72.64K | -147.29K | 179.92K | 28.14K | 17.55K | -701.10K | 719.32K | 192.33K | 127.68K | -104.90K | 0.00 | 0.00 |
| EBITDA | -3.63M | -3.91M | 4.19M | -2.39M | -930.40K | -951.91K | 0.00 | 0.00 | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| EBITDA Ratio | -5,029.28% | -4,958.28% | -4,057.63% | -5,847.68% | -2,224.03% | 0.00% | -138.24% | -48.64% | 17.11% | 113.14% | -167.63% | 0.00% | 0.00% |
| Operating Income | -3.86M | -3.65M | -2.74M | -2.57M | -930.40K | -594.24K | -470.39K | -393.66K | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| Operating Income Ratio | -5,347.41% | -5,059.02% | -3,850.95% | -6,287.34% | -2,293.38% | 0.00% | -55.51% | 58.80% | 149.58% | 232.34% | -68.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 224.51K | -279.73K | 6.93M | -464.55K | -82.89K | -375.22K | 826.92K | -719.32K | -192.33K | 0.00 | 104.90K | 0.00 | 0.00 |
| Income Before Tax | -3.63M | -3.91M | 4.18M | -3.04M | -1.01M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Income Before Tax Ratio | -5,036.04% | -5,419.25% | 5,868.30% | -7,422.52% | -2,497.71% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.16K | 24.88K | 92.35K | 34.79K | -513.85K | -62.91K | 696.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -3.70M | -3.91M | 3.90M | -3.13M | -1.05M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Net Income Ratio | -5,132.57% | -5,420.86% | 5,477.86% | -7,648.18% | -2,583.47% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| EPS | -1.20 | -1.71 | 2.06 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| EPS Diluted | -1.20 | -1.71 | 2.03 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| Weighted Avg Shares Out | 3.08M | 2.28M | 1.90M | 1.32M | 842.30K | 982.03K | 1.00M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
| Weighted Avg Shares Out (Dil) | 3.08M | 2.28M | 1.92M | 1.32M | 842.30K | 982.03K | 1.04M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis
Silo Plans to explore the use of Psychedelics to Target Inflammation Silo Plans to explore the use of Psychedelics to Target Inflammation
Silo Pharma to Present at Proactive's One2One Virtual Investor Forum
Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare...
Aion Therapeutic: Meet the team using artificial intelligence to create a full lineup of psychedelic and cannabis therapies
Aion Therapeutic Inc (CSE:AION), Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) and Silo Pharma Inc (OTCMKTS:SILO) are presenting at Proactive's next virtual showcase event on February 23. The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1...
Silo Pharma: Meet the team bridging the gap between traditional pharmaceuticals and psychedelic therapies
Silo Pharma Inc (OTCMKTS:SILO) will be presenting with Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) at Proactive's next virtual showcase event on February 23. The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1 PM...
Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds
Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space
Silo Pharma Inc. Engages CFN Enterprises Inc. to Reach Psychedelics Investor Audience
Silo Pharma Inc. is a biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved medical conditions.Whitefish, Montana--(Newsfile Corp. - February 10, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading...
Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as...
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology...
Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham
NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr....
Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets
NEW JERSEY , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has been requested by the OTC Markets Group...
Source: https://incomestatements.info
Category: Stock Reports